Cipla
Search results
Mobile computing is. future. Business is no more restricted to 4 walls. Proteus Vision is with you always, as an app on your phone. Allows you to perform your important business tasks, anytime, anywhere.
Welcome to MySunPharma! Please login below with your username and password.
Our scientists work closely with doctors, patients, and business development teams, to generate innovative concepts and ideas to harness market needs and synergies across therapeutic areas. Sun Pharma is the fourth largest global specialty generic pharmaceutical company with a presence in more than 100 countries.
Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of US$ 5.4 billion. Supported by 43 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.
Log in to sunsso.sunpharma.com to access Sun Pharma's secure and integrated platform for various applications and services.
Founded in 1983, India's largest pharma company Sun Pharma saw some of its toughest times between 2014 and 2018. However, under Dilip Shanghvi, Sun Pharma saw a turnaround. Watch this...
3 days ago · Sun Pharma announced FDA approval of Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata, marking a major milestone after acquiring Concert Pharmaceuticals for $576 million. The drug, with a five-year marketing exclusivity, boosts Sun Pharma's specialty business. Shares rose 2.58%. Clinical trials showed significant hair regrowth in patients
3 days ago · The Indian pharmaceutical giant Sun Pharmaceutical's stock soared up to 2.80 per cent, hitting all time high at 1711.95 per share on the BSE in Friday'’s intraday trade. This came after Sun Pharma announced that the US Food and Drug Administration (USFDA) has approved its new drug application for Deuruxolitinib, a new treatment for Alopecia Areata.
Jan 31, 2024 · Sun Pharmaceutical Industries Ltd reported a consolidated net profit of ₹2,523.75 crore, up 16.5% y-o-y, supported by robust sales, volume growth, and new product launches.
The stocks of Sun Pharma were trading in the green, up 2.26 per cent at ₹1656.30 on July 25, at 2:13 pm, on BSE. The company enjoys a market capitalisation of ₹3,97,212.20 crore, as BSE.
